Insulin-mediated activation of the L-arginine nitric oxide pathway in man, and its impairment in diabetes

PLoS One. 2013 May 2;8(5):e61840. doi: 10.1371/journal.pone.0061840. Print 2013.

Abstract

Aims/hypothesis: Impaired L-arginine transport has been reported in cardiovascular diseases, providing a possible mechanism for reduced nitric oxide (NO) production. Given that cardiovascular diseases are also associated with insulin resistance, and insulin is known to induce vasodilation via a NO-dependent pathway, we hypothesised that abnormal insulin modulation of L-arginine transport may contribute to vascular dysfunction in diabetes.

Methods: Forearm blood flow (FBF) responses to insulin and sodium nitroprusside (SNP) were measured in control and type 2 diabetic volunteers using venous occlusion plethysmography. Effects of intra-arterial insulin on the forearm veno-arterial flux of arginine and related amino acids were determined by HPLC. The effect of locally delivered insulin on arginine transport was assessed during an intra-arterial infusion of [4,5-(3)H] L-arginine.

Results: In controls, intrabrachial infusion of 5 mUnits/min insulin lead to a progressive rise in FBF (p<0.001) while this was not evident in diabetics. In support of this observation, we observed a concomitant, significant increase in the flux of N-hydroxy-L-arginine (the NO precursor) in controls (baseline vs. 60 mins insulin: 16.2±12.2 vs. 33.0±13.1 nmol/100 ml tissue/min; p<0.01), whilst no increase was observed in diabetics. Moreover, insulin augmented the clearance of [(3)H]L-arginine from the forearm circulation in controls (baseline vs insulin: 123±22 vs. 150±28 ml/min; p<0.05) but not in diabetics.

Conclusion: These findings suggest that insulin resistance may contribute substantially to the onset and development of cardiovascular disease in type 2 diabetics via abnormal insulin-mediated regulation of L-arginine transport.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arginine / metabolism*
  • Biological Transport / drug effects
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiopathology
  • Humans
  • Insulin / pharmacology*
  • Male
  • Middle Aged
  • Nitric Oxide / metabolism*
  • Nitroprusside / pharmacology
  • Vasodilation / drug effects

Substances

  • Insulin
  • Nitroprusside
  • Nitric Oxide
  • Arginine

Grants and funding

The study was supported by a grant from the National Heath and Medical Research Council of Australia. Dr. Rajapakse is a National Heart Foundation of Australia Post-doctoral Research Fellow (ID: PF09M4668). The study was also supported in part by the Victorian Government's operational Infrastructure Support Programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.